Hepatitis Treatment News
A Smart + Strong Site
Subscribe to:
Hep Magazine In Bulk
Hep Newsletter
Join Us:

Back to home » Hepatitis Treatment News


November 26, 2014
Lower Hep C Risk for Young IDUs on Opioid Maintenance Therapy
Taking opioid maintenance therapy with methadone or buprenorphine is linked to a 61 percent reduced risk of hepatitis C virus (HCV) among young injection drug users (IDUs) when compared with no substance abuse treatment
Hep C Treatment Guidelines for Priority Care Updated Again
Guidelines for hepatitis C have updated once again to emphasize that those with advanced fibrosis or compensated cirrhosis should be treated first.
November 25, 2014
Sovaldi-Based Hep C Regimens Work Well in the Real World
Hepatitis C treatments based on Gilead Sciences’ Sovaldi (sofosbuvir) are faring just as well in the real world as in clinical trials.
Harvoni Cures High Rates of People With Genotype 4 of Hep C
Gilead Sciences’ newly approved Harvoni (ledipasvir/sofosbuvir) cured nearly all people with genotype 4 of hepatitis C in a small trial.
Gilead’s 8-Week Hep C Cure Is Good for Genotype 3, Not 1 or 2
Eight weeks of Sovaldi and GS-5816, with or without ribavirin, cured high rates of people with genotype 3 of hepatitis C, but yielded unsatisfactory results among those with genotypes 1 and 2.
November 24, 2014
Gilead Sciences' Harvoni Is Approved in Europe
The European Commission has approved Gilead Sciences’ hepatitis C virus (HCV) treatment Harvoni (ledipasvir/sofosbuvir).
AbbVie's '3D' Regimen Plus Ribavirin Cures All With Hep C Genotype 4
AbbVie’s “3D” regimen plus ribavirin cured all people with genotype 4 of hepatitis C in a recent trial, plus 91 percent of those with genotype 4 treated without ribavirin.
November 21, 2014
Interferon Raises Chance of HBsAg Loss in People With Hepatitis B
Adding interferon to Viread (tenofovir) treatment for hepatitis B virus raised the likelihood of hep B surface antigen (HBsAg) loss in an ongoing trial, although the cure rate was still below 10 percent.
November 20, 2014
Harvoni Cures Almost All People With Hep C Coinfected With HIV
Twelve weeks of Gilead Sciences’ newly approved Harvoni cured nearly all people with genotype 1 of hepatitis C who were coinfected with HIV in a recent trial.
November 19, 2014
Hep C Cure Means Normal Lifespan for Those With Advanced Liver Disease
People who have hepatitis C and advanced liver fibrosis or cirrhosis and are cured of the virus may experience normal lifespan
November 18, 2014
12 Weeks of Harvoni and Ribavirin Cures 96% of Cirrhotics With HCV
Twelve weeks of Harvoni plus ribavirin cured nearly all highly treatment-experienced cirrhotic people with genotype 1 of hepatitis C virus in a recent trial.
Sovaldi and Olysio Cure High Rates of Hep C Post-Liver Transplant
Sovaldi (sofosbuvir) and Olysio (simeprevir), with or without ribavirin, cures over 90 percent of people with hepatitis C who have had a liver transplant.
November 17, 2014
High Post-Liver Transplant Survival Rates for People With HIV
HIV-positive people who have liver transplants because of liver cancer have high survival rates.
Comparing Hep B- Versus Hep C-Related Liver Cancer Outcomes
Treatment outcome and survival is similar between those with hepatitis B- and hepatitis C-related liver cancer, although those with advanced tumors and hep B have lower survival rates.
November 14, 2014
Harvoni Posts Good Cure Rates for Hepatitis Genotypes 3 and 6
Twelve weeks of Gilead Sciences’ Harvoni cured high rates of genotypes 3 and 6 of hepatitis C virus, with and without ribavirin, respectively.
November 13, 2014
U.S. Vets Have Low Rates of Hep B Testing and Treatment
Americans receiving care through the VA are infrequently tested for hepatitis B, and only a fraction of those who test positive are treated or receive liver cancer screening.
November 12, 2014
Excellent Results for 12 and 18 Weeks of Merck’s Dual Hep C Regimen
Twelve or 18 weeks of Merck’s grazoprevir/elbasvir, with or without ribavirin, cured 91 to 100 percent of hard-to-treat people with genotype 1 of hepatitis C.
November 11, 2014
4 Weeks of Merck’s Hep C Meds Plus Sovaldi Fails; 8 Weeks Does Well
Four weeks of Merck’s grazoprevir/elbasvir plus Gilead’s Sovaldi posted poor interim results in treating people with genotype 1 of hepatitis C.
Promising Results for New Hepatitis C Vaccine in Early Trial
A new hepatitis C virus (HCV) vaccine has yielded promising results in a Phase I trial, prompting significant immune activity against the virus.
November 10, 2014
Hep C Cure Lowers Risk of Death, Liver Cancer and Transplants
Achieving a cure for hepatitis C through interferon-based treatment reduces the risk of death, liver cancer and needing a liver transplant.
'TRIO' Regimen Cures 91% of Non-Cirrhotic Hep C Genotype 1
Twelve weeks of BMS's “TRIO” combo pill cured 91 percent of people with genotype 1 of hepatitis C who didn't have cirrhosis in a recent trial.
'TRIO' Plus Ribavirin Cures High Rates of Cirrhotic Genotype 1
Twelve weeks of BMS's “TRIO” combo pill, with ribavirin, cured 93 to 98 percent of people with genotype 1 of hep C who had cirrhosis in a recent trial.
Daclatasvir and Sovaldi Cure 86% to 90% of Hep C Genotype 3
Daclatasvir and Sovaldi (sofosbuvir) cured 86 percent to 90 percent of people with genotype 3 of hepatitis C in the ALLY-3 trial.
High Success For Harvoni Treating Coinfected Genotype 1
Harvoni (ledipasvir/sofosbuvir) is proving highly successful at treating hepatitis C among people coinfected with HIV and genotype 1 of hep C in an ongoing small trial.
ACH-3102 Plus Sovaldi Cures 100% of Genotype 1 in 8 Weeks
Eight weeks of ACH-3102 and Sovaldi (sofosbuvir) cured 100 percent of treatment-naive people with genotype 1 of hepatitis C in a recent study.
November 06, 2014
FDA Approves Olysio-Sovaldi Hep C Combo
The FDA has granted approval of Olysio (simeprevir) and Sovaldi (sofosbuvir) to be used in combination to treat genotype 1 of hepatitis C.
November 05, 2014
'3D' Hep C Treatment Improves Liver Health in Cirrhotics
Bristol-Myers Squibb’s investigatory “3D” hepatitis C treatment regimen rapidly improves indicators of liver health among those with cirrhosis.
November 03, 2014
The Thorny Economics of Treating Inmates’ Hep C With Sovaldi
Sovaldi (sofosbuvir) is a cost-effective treatment option for hepatitis C among the prison population when compared with other options.
Archives
   

November 2014
October 2014
September 2014
August 2014
July 2014
June 2014
May 2014
April 2014
March 2014
February 2014
January 2014
December 2013
November 2013
October 2013
September 2013
August 2013
July 2013
June 2013
May 2013
April 2013
March 2013
February 2013
January 2013
December 2012
November 2012
October 2012
September 2012
August 2012
July 2012
June 2012
May 2012
April 2012
March 2012
February 2012
January 2012
December 2011
November 2011
October 2011
September 2011
August 2011
July 2011
June 2011
May 2011
April 2011
March 2011
February 2011
January 2011
December 2010
November 2010
September 2010
August 2010
July 2010
June 2010
May 2010
April 2010
March 2010
February 2010
January 2010
December 2009
November 2009
October 2009
September 2009
August 2009
July 2009
June 2009
May 2009
April 2009
March 2009
February 2009
January 2009
December 2008
October 2008
September 2008
August 2008
July 2008
June 2008
May 2008
April 2008
March 2008
January 2008


QUICK LINKS

Current Issue
Forums
Poll
Blogs
Hep Stories
Calendar
Services Directory
Conference News
Top Stories
Treatment News
Hep Exclusives
All About Hepatitis
• Hepatitis A
Transmission
Prevention
Treatment
• Hepatitis B
Transmission
Prevention
Treatment
• Hepatitis C
Transmission
Prevention
Treatment
HCV/HIV Coinfection
Help Paying For Meds
Clinical Trials
TALK TO US
Tell us what you think
Poll
Are you willing to share your hepatitis C story?
Yes
No


Survey
Hepatitis C Reader Survey
HEP ON TWITTER
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.